APGE vs RUN · $2.34B cap vs P/E 6.0, rev $2.04B
Apogee Therapeutics, Inc. Common Stock (APGE) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Apogee Therapeutics, Inc. Common Stock (APGE) is a biotechnology company listed on US.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
APGE does not have a complete income-statement cache yet.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
APGE currently screens at market cap $2.34B. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the APGE and RUN stock pages for the full models.
Not investment advice.